



Clinical trial results:

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors

Summary

EudraCT number	2020-004163-12
Trial protocol	ES FR
Global end of trial date	27 August 2024

Results information

Result version number	v1 (current)
This version publication date	18 July 2025
First version publication date	18 July 2025

Trial information

Trial identification

Sponsor protocol code	2020-012-GLOB1
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04579757
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	HUTCHMED Limited
Sponsor organisation address	Building 4, 720 Cailun Road China (Shanghai) Pilot Free Trade Zone, Shanghai, China, 201203
Public contact	Nicky Murray, HUTCHMED Limited, +44 7738 881999, nicolam@hutch-med.com
Scientific contact	William Schelman, HUTCHMED Limited, +1 9733064490, williams@hutch-med.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 August 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 August 2024
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Part 1: To evaluate the safety and tolerability of surufatinib, thereby determining the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of surufatinib in combination with tislelizumab.

Part 2: To evaluate the objective response rate (ORR) as assessed by the investigator in patients with advanced solid tumors when treated with surufatinib in combination with tislelizumab according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.

Protection of trial subjects:

The study was conducted in accordance with the protocol, consensus and ethical principles derived from international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonization Good Clinical Practice guidelines, and applicable regulations and guidelines governing clinical study conduct.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 March 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 2
Country: Number of subjects enrolled	United States: 85
Worldwide total number of subjects	87
EEA total number of subjects	2

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	47
From 65 to 84 years	40
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This phase 1b/2, 2-part, open-label study was conducted in patients with advanced solid tumors. The study consisted of a dose-escalation phase and a dose expansion phase. A total of 12 patients in dose-escalation phase and 75 patients in dose-expansion phase were enrolled in this study.

Pre-assignment

Screening details:

The study was terminated early based on the strategic re-evaluation of clinical development of surufatinib in the United States and Europe with no safety concerns. No patients were enrolled in Cohort E1 (alveolar soft part sarcoma) in the dose-expansion phase, hence this cohort is not presented in results.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab

Arm description:

Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 milligrams (mg) orally once daily (QD) in combination with tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) until progressive disease (PD), unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm type	Experimental
Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Surufatinib 250 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm title	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab
------------------	--

Arm description:

Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Surufatinib 300 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm title	Dose Expansion Phase: Cohort A: CRC
------------------	-------------------------------------

Arm description:

Patients with microsatellite stable, locally advanced or metastatic colorectal cancer (CRC) that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm type	Experimental
Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Surufatinib 300 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm title	Dose Expansion Phase: Cohort B1: Thoracic NETs
------------------	--

Arm description:

Patients with thoracic neuroendocrine tumor (NET) who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm type	Experimental
Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:	
Surufatinib 300 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Arm title	Dose Expansion Phase: Cohort B2: GEP NETs
Arm description:	
Patients with gastroenteropancreatic (GEP) NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Arm type	Experimental
Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Surufatinib 300 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Arm title	Dose Expansion Phase: Cohort C: SCLC
Arm description:	
Patients with locally advanced or metastatic small-cell lung cancer (SCLC) that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Arm type	Experimental
Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Surufatinib 300 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	

Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm title	Dose Expansion Phase: Cohort D: GC
------------------	------------------------------------

Arm description:

Patients with microsatellite stable, programmed death-ligand 1 (PD-L1) $\geq 5\%$, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (gastric cancer [GC]), and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm type	Experimental
Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Surufatinib 300 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm title	Dose Expansion Phase: Cohort E2: UPS
------------------	--------------------------------------

Arm description:

Patients with undifferentiated pleomorphic sarcoma (UPS) who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm type	Experimental
Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Surufatinib 300 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Arm title	Dose Expansion Phase: Cohort F: ATC
Arm description:	
Patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) and who had a B-Raf kinase V600E (BRAFV600E) mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Arm type	Experimental
Investigational medicinal product name	Surufatinib
Investigational medicinal product code	HMPL-012
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Surufatinib 300 mg oral capsule was administered QD Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Tislelizumab 200 mg IV infusion was administered over 60 minutes in Cycles 1 and 2 and over at least 30 minutes in subsequent cycles (cycle duration: 3 weeks) until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	

Number of subjects in period 1	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC
Started	6	6	15
Completed	0	0	0
Not completed	6	6	15
Consent withdrawn by subject	1	1	-
Physician decision	-	-	-
Start of new therapy	-	-	-
Adverse event, non-fatal	-	-	-
Death	4	1	14
Study terminated by sponsor	-	-	-
Radiological or clinical PD	1	4	1

Number of subjects in period 1	Dose Expansion Phase: Cohort B1: Thoracic NETs	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC
Started	10	20	15
Completed	0	1	0
Not completed	10	19	15
Consent withdrawn by subject	-	2	1
Physician decision	2	1	1

Start of new therapy	-	2	1
Adverse event, non-fatal	2	1	1
Death	3	2	7
Study terminated by sponsor	-	2	-
Radiological or clinical PD	3	9	4

Number of subjects in period 1	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS	Dose Expansion Phase: Cohort F: ATC
Started	3	9	3
Completed	0	1	0
Not completed	3	8	3
Consent withdrawn by subject	-	3	-
Physician decision	1	-	-
Start of new therapy	-	-	-
Adverse event, non-fatal	-	-	-
Death	-	1	3
Study terminated by sponsor	-	2	-
Radiological or clinical PD	2	2	-

Baseline characteristics

Reporting groups

Reporting group title	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab
-----------------------	--

Reporting group description:

Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 milligrams (mg) orally once daily (QD) in combination with tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) until progressive disease (PD), unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab
-----------------------	--

Reporting group description:

Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort A: CRC
-----------------------	-------------------------------------

Reporting group description:

Patients with microsatellite stable, locally advanced or metastatic colorectal cancer (CRC) that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort B1: Thoracic NETs
-----------------------	--

Reporting group description:

Patients with thoracic neuroendocrine tumor (NET) who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort B2: GEP NETs
-----------------------	---

Reporting group description:

Patients with gastroenteropancreatic (GEP) NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort C: SCLC
-----------------------	--------------------------------------

Reporting group description:

Patients with locally advanced or metastatic small-cell lung cancer (SCLC) that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort D: GC
-----------------------	------------------------------------

Reporting group description:

Patients with microsatellite stable, programmed death-ligand 1 (PD-L1) $\geq 5\%$, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (gastric cancer [GC]), and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort E2: UPS
-----------------------	--------------------------------------

Reporting group description:

Patients with undifferentiated pleomorphic sarcoma (UPS) who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort F: ATC
-----------------------	-------------------------------------

Reporting group description:

Patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) and who had a B-Raf kinase V600E (BRAFV600E) mutation were previously treated with 1 line of systemic therapy (not including

radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC
Number of subjects	6	6	15
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	62.5 ± 14.69	68.2 ± 9.83	53.5 ± 11.99
Gender categorical Units: Subjects			
Female	1	2	8
Male	5	4	7
Ethnicity Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	5	6	15
Unknown or Not Reported	1	0	0
Race Units: Subjects			
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	1	0	0
Black or African American	0	1	4
White	3	3	10
More than one race	1	1	0
Unknown or Not Reported	1	1	1

Reporting group values	Dose Expansion Phase: Cohort B1: Thoracic NETs	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC
Number of subjects	10	20	15
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	58.6 ± 9.70	63.2 ± 9.23	58.1 ± 14.27
Gender categorical Units: Subjects			
Female	4	10	8
Male	6	10	7

Ethnicity			
Units: Subjects			
Hispanic or Latino	0	2	1
Not Hispanic or Latino	9	18	13
Unknown or Not Reported	1	0	1
Race			
Units: Subjects			
Asian	1	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	3	1
White	8	17	12
More than one race	0	0	1
Unknown or Not Reported	1	0	1

Reporting group values	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS	Dose Expansion Phase: Cohort F: ATC
Number of subjects	3	9	3
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	60.7	59.9	63.0
standard deviation	± 5.86	± 13.94	± 19.05
Gender categorical			
Units: Subjects			
Female	0	6	1
Male	3	3	2
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	1	0
Not Hispanic or Latino	3	8	2
Unknown or Not Reported	0	0	1
Race			
Units: Subjects			
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	3	9	3
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Reporting group values	Total		
Number of subjects	87		
Age categorical			
Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Female	40		
Male	47		
Ethnicity Units: Subjects			
Hispanic or Latino	4		
Not Hispanic or Latino	79		
Unknown or Not Reported	4		
Race Units: Subjects			
Asian	1		
Native Hawaiian or Other Pacific Islander	1		
Black or African American	9		
White	68		
More than one race	3		
Unknown or Not Reported	5		

End points

End points reporting groups

Reporting group title	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab
Reporting group description: Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 milligrams (mg) orally once daily (QD) in combination with tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) until progressive disease (PD), unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Reporting group title	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab
Reporting group description: Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Reporting group title	Dose Expansion Phase: Cohort A: CRC
Reporting group description: Patients with microsatellite stable, locally advanced or metastatic colorectal cancer (CRC) that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Reporting group title	Dose Expansion Phase: Cohort B1: Thoracic NETs
Reporting group description: Patients with thoracic neuroendocrine tumor (NET) who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Reporting group title	Dose Expansion Phase: Cohort B2: GEP NETs
Reporting group description: Patients with gastroenteropancreatic (GEP) NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Reporting group title	Dose Expansion Phase: Cohort C: SCLC
Reporting group description: Patients with locally advanced or metastatic small-cell lung cancer (SCLC) that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Reporting group title	Dose Expansion Phase: Cohort D: GC
Reporting group description: Patients with microsatellite stable, programmed death-ligand 1 (PD-L1) $\geq 5\%$, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (gastric cancer [GC]), and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Reporting group title	Dose Expansion Phase: Cohort E2: UPS
Reporting group description: Patients with undifferentiated pleomorphic sarcoma (UPS) who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	
Reporting group title	Dose Expansion Phase: Cohort F: ATC
Reporting group description: Patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) and who had a B-Raf kinase V600E (BRAFV600E) mutation were previously treated with 1 line of systemic therapy (not including	

radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Primary: Dose Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs)

End point title	Dose Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) ^{[1][2]}
-----------------	--

End point description:

Per National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) v5.0, DLT=any following AE: Nonhematologic toxicity: \geq grade (G) 3 nonhematologic toxicity, except: G3 fatigue lasting <7 days, G3 rash returning to baseline or \leq G1 within 7 days with treatment, G3 hypertension downgraded to \leq G1 within 7 days with therapy, G3 endocrinopathy controlled by hormonal replacement with no hospitalization and resolving to \leq G1 within 7 days, \geq G3 amylase/lipase elevation without symptoms of pancreatitis, G3 nausea/vomiting or diarrhea for <72 hours with care, \geq G3 electrolyte abnormality lasting up to 72 hours and resolving with treatment. Hematologic toxicity: \geq G3 febrile neutropenia, G4 neutropenia; G4 thrombocytopenia lasting >7 days, G3 thrombocytopenia with severe bleeding, G4 anemia. DLT-evaluable analysis set=all patients enrolled in dose escalation phase, evaluable for DLT assessment; received $\geq 85\%$ of surufatinib and $\geq 67\%$ of tislelizumab administration during DLT assessment or had a DLT.

End point type	Primary
----------------	---------

End point timeframe:

From the first dose of study drug (Day 1) up to Day 21 of Cycle 1 (cycle duration: 3 weeks)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only dose escalation phase arms were analyzed for this endpoint.

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: patients	1	1		

Statistical analyses

No statistical analyses for this end point

Primary: Dose Escalation Phase: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation

End point title	Dose Escalation Phase: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation ^{[3][4]}
-----------------	---

End point description:

An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment in humans, whether or not considered related to the treatment. An AE was

considered "serious" if, in the view of either the investigator or sponsor, it resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, was a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study treatment and up to 30 days after the date of last study treatment administration. The safety analysis set (SAS) included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

End point type	Primary
----------------	---------

End point timeframe:

From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only dose escalation phase arms were analyzed for this endpoint.

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: patients				
Any TEAEs	6	6		
Any TSEAEs	5	3		
Any TEAEs leading to surufatinib discontinuation	3	0		
Any TEAEs leading to tislelizumab discontinuation	3	0		

Statistical analyses

No statistical analyses for this end point

Primary: Dose Expansion Phase: Objective Response Rate

End point title	Dose Expansion Phase: Objective Response Rate ^{[5][6]}
-----------------	---

End point description:

ORR was defined as the percentage of patients with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using RECIST v1.1. BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Here, +/- 9999 = values were not estimable as there were no patients with CR or PR in that disease cohort.

End point type	Primary
----------------	---------

End point timeframe:

Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 37 months

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only dose expansion phase arms were analyzed for this endpoint.

End point values	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	10	20	15
Units: percentage of patients				
number (confidence interval 95%)	6.7 (0.2 to 31.9)	0 (-9999 to 9999)	15.0 (3.2 to 37.9)	13.3 (1.7 to 40.5)

End point values	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS	Dose Expansion Phase: Cohort F: ATC	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3	9	3	
Units: percentage of patients				
number (confidence interval 95%)	33.3 (0.8 to 90.6)	44.4 (13.7 to 78.8)	0 (-9999 to 9999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation Phase: Objective Response Rate

End point title	Dose Escalation Phase: Objective Response Rate ^[7]
-----------------	---

End point description:

ORR was defined as the percentage of patients with a confirmed BOR of CR or PR as determined by the investigator using RECIST v1.1. BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Here, +/- 9999 = values were not estimable as there were no patients with CR or PR in that disease cohort.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only dose escalation phase arms were analyzed for this endpoint.

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: percentage of patients				
number (confidence interval 95%)	0 (-9999 to 9999)	0 (-9999 to 9999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation and Dose Expansion Phases: Progression-free Survival (PFS)

End point title	Dose Escalation and Dose Expansion Phases: Progression-free Survival (PFS)
-----------------	--

End point description:

PFS was defined as the time from the start of study treatment until the first radiographic documentation of objective progression as assessed by the investigator using RECIST v1.1, or death from any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Here, 9999 = values were not estimable due to insufficient number of patients with events at study closure.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	15	10
Units: months				
median (confidence interval 95%)	1.5 (1.2 to 9999)	6.0 (1.8 to 9999)	4.7 (2.7 to 5.4)	4.5 (0.3 to 9999)

End point values	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS
------------------	---	--------------------------------------	------------------------------------	--------------------------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	15	3	9
Units: months				
median (confidence interval 95%)	7.4 (3.1 to 20.0)	1.4 (1.0 to 4.0)	9.6 (5.6 to 9999)	9999 (1.3 to 9999)

End point values	Dose Expansion Phase: Cohort F: ATC			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: months				
median (confidence interval 95%)	2.8 (1.2 to 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation and Dose Expansion Phases: Disease Control Rate (DCR)

End point title	Dose Escalation and Dose Expansion Phases: Disease Control Rate (DCR)
-----------------	---

End point description:

DCR was defined as percentage of patients with a BOR of CR, PR, or stable disease (SD) lasting for at least 7 weeks as determined by the investigator using RECIST v1.1. BOR was defined as best response recorded from start of study treatment until documented RECIST v1.1 progression or start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum on study. SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Here, +/- 9999 = values were not estimable due to no patients with CR, PR, or SD for at least 7 weeks.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	15	10
Units: percentage of patients				
number (confidence interval 95%)	0 (-9999 to 9999)	66.7 (22.3 to 95.7)	66.7 (38.4 to 88.2)	50.0 (18.7 to 81.3)

End point values	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	15	3	9
Units: percentage of patients				
number (confidence interval 95%)	70.0 (45.7 to 88.1)	26.7 (7.8 to 55.1)	66.7 (9.4 to 99.2)	55.6 (21.2 to 86.3)

End point values	Dose Expansion Phase: Cohort F: ATC			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: percentage of patients				
number (confidence interval 95%)	33.3 (0.8 to 90.6)			

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation and Dose Expansion Phases: Clinical Benefit Rate (CBR)

End point title	Dose Escalation and Dose Expansion Phases: Clinical Benefit Rate (CBR)
-----------------	--

End point description:

CBR was defined as percentage of patients with BOR of CR, PR, or durable SD as determined by investigator using RECIST v1.1. Durable SD was SD for at least 6 months. BOR was defined as best response recorded from start of study treatment until documented RECIST v1.1 progression or start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum on study. SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Here, +/- 9999 = values were not estimable due to no patients with CR, PR, or SD lasting for at least 6 months.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	15	10
Units: percentage of patients				
number (confidence interval 95%)	0 (-9999 to 9999)	50.0 (11.8 to 88.2)	20.0 (4.3 to 48.1)	20.0 (2.5 to 55.6)

End point values	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	15	3	9
Units: percentage of patients				
number (confidence interval 95%)	40.0 (19.1 to 63.9)	13.3 (1.7 to 40.5)	33.3 (0.8 to 90.6)	44.4 (13.7 to 78.8)

End point values	Dose Expansion Phase: Cohort F: ATC			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: percentage of patients				
number (confidence interval 95%)	0 (-9999 to 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation and Dose Expansion Phases: Duration of Response (DoR)

End point title	Dose Escalation and Dose Expansion Phases: Duration of Response (DoR)
-----------------	---

End point description:

DoR was defined as the time from the first occurrence of PR or CR by RECIST v1.1, until PD or death, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Only those patients with PR or CR (responders) were included in the analysis. Here, +/- 9999 = values were not estimable due to insufficient number of patients with events at study closure.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[8]	0 ^[9]	1	0 ^[10]
Units: months				
median (confidence interval 95%)	(to)	(to)	9999 (9999 to 9999)	(to)

Notes:

[8] - There were no patients with PR or CR (responders) in this cohort.

[9] - There were no patients with PR or CR (responders) in this cohort.

[10] - There were no patients with PR or CR (responders) in this cohort.

End point values	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	2	1	4
Units: months				
median (confidence interval 95%)	9999 (15.0 to 9999)	8.3 (5.8 to 9999)	11.0 (-9999 to 9999)	9999 (9999 to 9999)

End point values	Dose Expansion Phase: Cohort F: ATC			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[11]			
Units: months				
median (confidence interval 95%)	(to)			

Notes:

[11] - There were no patients with PR or CR (responders) in this cohort.

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation and Dose Expansion Phases: Time to Response (TTR)

End point title	Dose Escalation and Dose Expansion Phases: Time to Response (TTR)
-----------------	---

End point description:

TTR was defined as the time from start of study treatment until the date of first documented objective response, either CR or PR (whichever status was recorded first), according to RECIST v1.1. CR was

defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Only those patients with PR or CR (responders) were included in the analysis. Here, +/- 9999 = values were not estimable due to insufficient number of patients with events at study closure.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[12]	0 ^[13]	1	0 ^[14]
Units: months				
median (confidence interval 95%)	(to)	(to)	2.7 (-9999 to 9999)	(to)

Notes:

[12] - There were no patients with PR or CR (responders) in this cohort.

[13] - There were no patients with PR or CR (responders) in this cohort.

[14] - There were no patients with PR or CR (responders) in this cohort.

End point values	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	2	1	4
Units: months				
median (confidence interval 95%)	3.9 (2.7 to 9999)	3.5 (1.3 to 9999)	2.7 (-9999 to 9999)	1.4 (1.2 to 9999)

End point values	Dose Expansion Phase: Cohort F: ATC			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[15]			
Units: months				
median (confidence interval 95%)	(to)			

Notes:

[15] - There were no patients with PR or CR (responders) in this cohort.

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib

End point title	Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib
End point description:	
Blood samples were collected at the specified timepoints to determine plasma concentration of surufatinib. The pharmacokinetic (PK) analysis set included all patients with at least 1 quantifiable concentration of surufatinib or tislelizumab. Here, n = number of patients with data collected at specified timepoints. 9999 = values were not estimable as they were below the lower limit of quantification (LLOQ) of 1.00 nanograms per milliliter (ng/mL). 99999 = standard deviation (SD) was not estimable for 1 patient. 55555 = no patients were analyzed. C = Cycle and D = Day.	
End point type	Secondary
End point timeframe:	
Pre-dose on Day 1 of Cycles 1, 2, 5, 9, 17 and on Days 8 and 15 of Cycle 1; 2 to 4 hours (h) post-dose on Days 1 and 15 of Cycle 1 (cycle duration: 3 weeks)	

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	15	10
Units: ng/mL				
arithmetic mean (standard deviation)				
C1D1: Pre-dose (n=5,6,15,10,19,15,3,9,2)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)
C1D1: 2 to 4 h post-dose (n=6,6,15,10,19,15,3,9,2)	293.03 (± 244.593)	576.00 (± 415.108)	426.62 (± 312.209)	276.36 (± 243.080)
C1D8: Pre-dose (n=4,6,12,5,14,9,2,6,1)	77.00 (± 44.023)	189.93 (± 113.750)	170.33 (± 131.533)	100.12 (± 71.600)
C1D15: Pre-dose (n=5,5,11,4,15,10,2,6,0)	64.36 (± 15.246)	181.56 (± 125.156)	135.96 (± 83.673)	159.00 (± 139.802)
C1D15: 2 to 4 h post-dose (n=3,3,13,4,12,11,2,7,0)	318.67 (± 146.770)	757.33 (± 498.399)	657.54 (± 369.146)	354.25 (± 52.519)
C2D1: Pre-dose (n=5,4,10,3,9,11,2,2,1)	45.82 (± 27.567)	96.80 (± 38.895)	151.44 (± 99.521)	89.37 (± 53.475)
C5D1: Pre-dose (n=0,2,3,1,4,2,0,0,0)	55555 (± 55555)	55.25 (± 8.132)	141.20 (± 117.885)	41.00 (± 99999)
C9D1: Pre-dose (n=0,1,0,0,3,1,0,0,0)	55555 (± 55555)	65.90 (± 99999)	55555 (± 55555)	55555 (± 55555)
C17D1: Pre-dose (n=0,0,0,0,1,0,0,0,0)	55555 (± 55555)	55555 (± 55555)	55555 (± 55555)	55555 (± 55555)

End point values	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	19	15	3	9
Units: ng/mL				
arithmetic mean (standard deviation)				

C1D1: Pre-dose (n=5,6,15,10,19,15,3,9,2)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)
C1D1: 2 to 4 h post-dose (n=6,6,15,10,19,15,3,9,2)	294.13 (± 292.335)	406.97 (± 212.791)	506.27 (± 653.616)	275.64 (± 165.937)
C1D8: Pre-dose (n=4,6,12,5,14,9,2,6,1)	92.26 (± 63.901)	122.80 (± 70.875)	109.10 (± 18.243)	97.70 (± 40.471)
C1D15: Pre-dose (n=5,5,11,4,15,10,2,6,0)	84.95 (± 70.121)	96.79 (± 43.933)	111.05 (± 19.728)	118.92 (± 75.457)
C1D15: 2 to 4 h post-dose (n=3,3,13,4,12,11,2,7,0)	471.78 (± 330.598)	425.75 (± 235.698)	188.00 (± 41.012)	518.00 (± 302.182)
C2D1: Pre-dose (n=5,4,10,3,9,11,2,2,1)	75.94 (± 53.028)	117.68 (± 79.721)	146.50 (± 26.163)	71.95 (± 9.405)
C5D1: Pre-dose (n=0,2,3,1,4,2,0,0,0)	61.08 (± 22.279)	105.70 (± 54.164)	55555 (± 55555)	55555 (± 55555)
C9D1: Pre-dose (n=0,1,0,0,3,1,0,0,0)	87.20 (± 14.964)	41.70 (± 99999)	55555 (± 55555)	55555 (± 55555)
C17D1: Pre-dose (n=0,0,0,0,1,0,0,0,0)	85.10 (± 99999)	55555 (± 55555)	55555 (± 55555)	55555 (± 55555)

End point values	Dose Expansion Phase: Cohort F: ATC			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: ng/mL				
arithmetic mean (standard deviation)				
C1D1: Pre-dose (n=5,6,15,10,19,15,3,9,2)	9999 (± 9999)			
C1D1: 2 to 4 h post-dose (n=6,6,15,10,19,15,3,9,2)	782.50 (± 463.155)			
C1D8: Pre-dose (n=4,6,12,5,14,9,2,6,1)	709.00 (± 99999)			
C1D15: Pre-dose (n=5,5,11,4,15,10,2,6,0)	55555 (± 55555)			
C1D15: 2 to 4 h post-dose (n=3,3,13,4,12,11,2,7,0)	55555 (± 55555)			
C2D1: Pre-dose (n=5,4,10,3,9,11,2,2,1)	147.00 (± 99999)			
C5D1: Pre-dose (n=0,2,3,1,4,2,0,0,0)	55555 (± 55555)			
C9D1: Pre-dose (n=0,1,0,0,3,1,0,0,0)	55555 (± 55555)			
C17D1: Pre-dose (n=0,0,0,0,1,0,0,0,0)	55555 (± 55555)			

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab

End point title	Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab
-----------------	--

End point description:

Blood samples were collected at the specified timepoints to determine serum concentration of tislelizumab. The PK analysis set included all patients with at least 1 quantifiable concentration of surufatinib or tislelizumab. Here, n = number of patients with data collected at specified timepoints. 9999 = values were not estimable as they were below the LLOQ of 400 ng/mL. 99999 = SD was not estimable for 1 patient. 55555 = no patients were analyzed. C = Cycle and D = Day.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-infusion on Day 1 of Cycles 1, 2, 5, 9, 17; end of infusion on Day 1 of Cycles 1 and 5; on Days 8 and 15 of Cycle 1 (cycle duration: 3 weeks)

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	15	10
Units: ng/mL				
arithmetic mean (standard deviation)				
C1D1: Pre-infusion (n=6,6,15,9,19,15,3,9,2)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)
C1D1: End of infusion (n=6,6,15,10,19,15,3,9,2)	44550.0 (± 7420.98)	62750.0 (± 17420.53)	57233.3 (± 8846.28)	70990.0 (± 41600.73)
C1D8 (n=6,6,13,8,18,12,3,8,2)	16980.0 (± 6850.75)	26216.7 (± 7702.32)	26446.2 (± 6387.83)	29575.0 (± 5751.46)
C1D15 (n=6,6,12,7,16,12,2,8,2)	14296.7 (± 5945.36)	17900.0 (± 5297.55)	17414.2 (± 4199.94)	20571.4 (± 2817.63)
C2D1: Pre-infusion (n=5,5,14,6,15,12,2,8,2)	9564.0 (± 7871.14)	13804.0 (± 4782.16)	13858.6 (± 4730.49)	14033.3 (± 2436.12)
C5D1: Pre-infusion (n=0,3,8,1,8,4,1,3,1)	55555 (± 55555)	24400.0 (± 14028.90)	36412.5 (± 34947.57)	46400.0 (± 99999)
C5D1: End of infusion (n=0,3,7,2,8,4,1,3,1)	55555 (± 55555)	87166.7 (± 34425.04)	102500.0 (± 26662.02)	117500.0 (± 6363.96)
C9D1: Pre-infusion (n=0,2,1,1,5,2,0,2,0)	55555 (± 55555)	22700.0 (± 4101.22)	44800.0 (± 99999)	50000.0 (± 99999)
C17D1: Pre-infusion (n=0,0,0,1,3,1,0,1,0)	55555 (± 55555)	55555 (± 55555)	55555 (± 55555)	55555 (± 55555)

End point values	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	19	15	3	9
Units: ng/mL				
arithmetic mean (standard deviation)				
C1D1: Pre-infusion (n=6,6,15,9,19,15,3,9,2)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)
C1D1: End of infusion (n=6,6,15,10,19,15,3,9,2)	61136.8 (± 15927.90)	66220.0 (± 17336.43)	67966.7 (± 45015.59)	55955.6 (± 15499.61)
C1D8 (n=6,6,13,8,18,12,3,8,2)	32244.4 (± 7253.58)	35450.0 (± 8899.39)	38233.3 (± 35800.33)	25475.0 (± 6549.10)

C1D15 (n=6,6,12,7,16,12,2,8,2)	24506.3 (± 6403.07)	23783.3 (± 4274.20)	43950.0 (± 40658.64)	19300.0 (± 4755.45)
C2D1: Pre-infusion (n=5,5,14,6,15,12,2,8,2)	18020.0 (± 5688.23)	17725.0 (± 3860.55)	38000.0 (± 36910.97)	12161.3 (± 4443.93)
C5D1: Pre-infusion (n=0,3,8,1,8,4,1,3,1)	41575.0 (± 10065.32)	31225.0 (± 12388.81)	20100.0 (± 99999)	19200.0 (± 3143.25)
C5D1: End of infusion (n=0,3,7,2,8,4,1,3,1)	113475.0 (± 16286.34)	117550.0 (± 43800.65)	80800.0 (± 99999)	103033.3 (± 17737.06)
C9D1: Pre-infusion (n=0,2,1,1,5,2,0,2,0)	45500.0 (± 5384.24)	41200.0 (± 24607.32)	55555 (± 55555)	41100.0 (± 16970.56)
C17D1: Pre-infusion (n=0,0,0,1,3,1,0,1,0)	44766.7 (± 12196.86)	51900.0 (± 99999)	55555 (± 55555)	47300.0 (± 99999)

End point values	Dose Expansion Phase: Cohort F: ATC			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: ng/mL				
arithmetic mean (standard deviation)				
C1D1: Pre-infusion (n=6,6,15,9,19,15,3,9,2)	9999 (± 9999)			
C1D1: End of infusion (n=6,6,15,10,19,15,3,9,2)	42200.0 (± 12727.92)			
C1D8 (n=6,6,13,8,18,12,3,8,2)	16050.0 (± 1767.77)			
C1D15 (n=6,6,12,7,16,12,2,8,2)	10940.0 (± 2489.02)			
C2D1: Pre-infusion (n=5,5,14,6,15,12,2,8,2)	7640.0 (± 2729.43)			
C5D1: Pre-infusion (n=0,3,8,1,8,4,1,3,1)	22700.0 (± 99999)			
C5D1: End of infusion (n=0,3,7,2,8,4,1,3,1)	69000.0 (± 99999)			
C9D1: Pre-infusion (n=0,2,1,1,5,2,0,2,0)	55555 (± 55555)			
C17D1: Pre-infusion (n=0,0,0,1,3,1,0,1,0)	55555 (± 55555)			

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Escalation and Dose Expansion Phases: Number of Patients With Antidrug Antibodies (ADA) to Tislelizumab

End point title	Dose Escalation and Dose Expansion Phases: Number of Patients With Antidrug Antibodies (ADA) to Tislelizumab
-----------------	--

End point description:

Blood samples were collected at the specified timepoints to detect ADAs to tislelizumab. Treatment-boosted ADA was defined as ADA positive at baseline that was boosted to a 4-fold or higher-level following treatment administration. Treatment-induced ADA was defined as ADA negative at baseline and ADA positive post-baseline. The ADA analysis set included all patients who received at least 1 dose of tislelizumab and had a baseline and at least 1 post-baseline ADA result.

End point type	Secondary
End point timeframe:	
From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase	

End point values	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	5	14	8
Units: patients				
Treatment-Boosted ADA	0	0	2	0
Treatment-Induced ADA	2	2	5	3

End point values	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	13	2	9
Units: patients				
Treatment-Boosted ADA	0	0	0	0
Treatment-Induced ADA	5	1	0	5

End point values	Dose Expansion Phase: Cohort F: ATC			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: patients				
Treatment-Boosted ADA	0			
Treatment-Induced ADA	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Expansion Phase (Cohorts A and F): Overall Survival (OS)

End point title	Dose Expansion Phase (Cohorts A and F): Overall Survival
-----------------	--

End point description:

OS was defined as the time from the start of study treatment until the date of death due to any cause. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. As pre-specified in the protocol and statistical analysis plan (SAP), OS was assessed only in Cohort A (CRC) and Cohort F (ATC) of the dose expansion phase. Here, 9999 = value was not estimable due to insufficient number of patients with events at study closure.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study treatment (Day 1) up to date of death due to any cause, up to approximately 42 months

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the protocol and statistical analysis plan (SAP), this endpoint was analyzed only in Cohort A (CRC) and Cohort F (ATC) of the dose expansion phase.

End point values	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort F: ATC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	15	3		
Units: months				
median (confidence interval 95%)	7.1 (4.8 to 11.8)	5.3 (2.8 to 9999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Dose Expansion Phase: Number of Patients With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and TEAEs Leading to Treatment Discontinuation

End point title	Dose Expansion Phase: Number of Patients With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and TEAEs Leading to Treatment Discontinuation ^[17]
-----------------	---

End point description:

An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment in humans, whether or not considered related to the treatment. An AE was considered "serious" if, in the view of either the investigator or sponsor, it resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, was a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study treatment and up to 30 days after the date of last study treatment administration. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 33 months

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only dose expansion phase arms were analyzed for this endpoint.

End point values	Dose Expansion Phase: Cohort A: CRC	Dose Expansion Phase: Cohort B1: Thoracic NETs	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	10	20	15
Units: patients				
Any TEAEs	14	10	20	15
Any TSEAEs	9	5	9	8
Any TEAEs leading to surufatinib discontinuation	3	2	5	5
Any TEAEs leading to tislelizumab discontinuation	6	2	6	5

End point values	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS	Dose Expansion Phase: Cohort F: ATC	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3	9	3	
Units: patients				
Any TEAEs	3	9	3	
Any TSEAEs	0	4	1	
Any TEAEs leading to surufatinib discontinuation	0	2	0	
Any TEAEs leading to tislelizumab discontinuation	0	2	0	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AEs: From first dose (Day 1) up to 30 days after last dose of study treatment, approximately 9 months for dose escalation and 33 months for dose expansion phase. Deaths: From signing of informed consent form up to end of follow up, approximately 42 months.

Adverse event reporting additional description:

The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.0
--------------------	------

Reporting groups

Reporting group title	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab
-----------------------	--

Reporting group description:

Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab
-----------------------	--

Reporting group description:

Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort A: CRC
-----------------------	-------------------------------------

Reporting group description:

Patients with microsatellite stable, locally advanced or metastatic CRC that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort B1: Thoracic NETs
-----------------------	--

Reporting group description:

Patients with thoracic NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort B2: GEP NETs
-----------------------	---

Reporting group description:

Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort C: SCLC
-----------------------	--------------------------------------

Reporting group description:

Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort D: GC
-----------------------	------------------------------------

Reporting group description:

Patients with microsatellite stable, PD-L1 $\geq 5\%$, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC), and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to

follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort E2: UPS
-----------------------	--------------------------------------

Reporting group description:

Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Reporting group title	Dose Expansion Phase: Cohort F: ATC
-----------------------	-------------------------------------

Reporting group description:

Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.

Serious adverse events	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 6 (83.33%)	3 / 6 (50.00%)	9 / 15 (60.00%)
number of deaths (all causes)	4	1	14
number of deaths resulting from adverse events	2	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant neoplasm progression			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Disease progression			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Acute respiratory failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Liver function test increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic rupture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial flutter			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive encephalopathy			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nausea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic fistula			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dyskinesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary obstruction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperhidrosis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Clostridium difficile infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Dose Expansion Phase: Cohort B1: Thoracic NETs	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 10 (50.00%)	9 / 20 (45.00%)	8 / 15 (53.33%)
number of deaths (all causes)	4	2	8
number of deaths resulting from adverse events	1	1	5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant neoplasm progression			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Basal cell carcinoma			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Disease progression			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pyrexia			

subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			

Delirium			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Liver function test increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic rupture			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac disorders			
Atrial flutter			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			

subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myocarditis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive encephalopathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 10 (10.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Enteritis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Large intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic fistula			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			

Biliary dyskinesia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperhidrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			

subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Sepsis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Abdominal infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS	Dose Expansion Phase: Cohort F: ATC
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	4 / 9 (44.44%)	1 / 3 (33.33%)
number of deaths (all causes)	0	1	3
number of deaths resulting from	0	0	0

adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant neoplasm progression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Disease progression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Investigations			
Liver function test increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic rupture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial flutter			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive encephalopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic fistula			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dyskinesia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary obstruction			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperhidrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			

Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab	Dose Expansion Phase: Cohort A: CRC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 6 (83.33%)	6 / 6 (100.00%)	14 / 15 (93.33%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			

subjects affected / exposed	0 / 6 (0.00%)	2 / 6 (33.33%)	10 / 15 (66.67%)
occurrences (all)	0	3	23
Flushing			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	3
Orthostatic hypotension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Vasculitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 6 (50.00%)	3 / 6 (50.00%)	6 / 15 (40.00%)
occurrences (all)	3	5	9
Oedema peripheral			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	2 / 15 (13.33%)
occurrences (all)	2	1	2
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	3 / 15 (20.00%)
occurrences (all)	0	1	3
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Chills			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	1	1	0
Localised oedema			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Gait disturbance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Catheter site haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Catheter site haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Facial pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Medical device site pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Peripheral swelling			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0
Xerosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Reproductive system and breast disorders Pelvic pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Gynaecomastia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 6 (33.33%) 2	0 / 15 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	3 / 6 (50.00%) 3	1 / 15 (6.67%) 1
Epistaxis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Nasal congestion			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Atelectasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sneezing			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			

Confusional state			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Insomnia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Anxiety			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Depressed mood			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Panic attack			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Restlessness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	4 / 15 (26.67%)
occurrences (all)	0	1	7
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	3 / 15 (20.00%)
occurrences (all)	0	1	3
Blood creatinine increased			

subjects affected / exposed	0 / 6 (0.00%)	2 / 6 (33.33%)	5 / 15 (33.33%)
occurrences (all)	0	3	7
Weight decreased			
subjects affected / exposed	1 / 6 (16.67%)	4 / 6 (66.67%)	4 / 15 (26.67%)
occurrences (all)	1	4	5
Blood bilirubin increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	3 / 15 (20.00%)
occurrences (all)	0	1	5
Lipase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	2
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	4 / 15 (26.67%)
occurrences (all)	0	0	5
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	2
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Amylase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Lymphocyte count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	2
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	2
Blood creatine increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
White blood cell count increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Fall			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Incision site discharge			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Postoperative wound complication			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Wound dehiscence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	2
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 6 (0.00%)	2 / 6 (33.33%)	2 / 15 (13.33%)
occurrences (all)	0	2	2
Tachycardia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Aortic valve disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 6 (33.33%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	2	0	2
Dizziness			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	1	1	0
Dysgeusia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	3
Paraesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Lethargy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Burning sensation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Metabolic encephalopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Somnolence			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Spinal cord compression subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 2	1 / 6 (16.67%) 3	1 / 15 (6.67%) 1
Coagulopathy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Ear and labyrinth disorders			
Hypoacusis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Vertigo subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0
Ear pruritus subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Vitreous floaters subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 3	3 / 6 (50.00%) 3	10 / 15 (66.67%) 18
Diarrhoea			

subjects affected / exposed	1 / 6 (16.67%)	3 / 6 (50.00%)	6 / 15 (40.00%)
occurrences (all)	1	4	14
Vomiting			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	7 / 15 (46.67%)
occurrences (all)	1	1	13
Abdominal pain			
subjects affected / exposed	2 / 6 (33.33%)	0 / 6 (0.00%)	3 / 15 (20.00%)
occurrences (all)	3	0	4
Constipation			
subjects affected / exposed	1 / 6 (16.67%)	2 / 6 (33.33%)	2 / 15 (13.33%)
occurrences (all)	1	2	4
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	2
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	3 / 15 (20.00%)
occurrences (all)	0	0	4
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	2
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Ascites			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Large intestinal obstruction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	2
Mouth haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Odynophagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Pancreatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Proctalgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Small intestinal obstruction subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Hepatobiliary disorders			
Immune-mediated hepatitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Biliary obstruction subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Hepatic artery thrombosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Hepatic cirrhosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0
Skin and subcutaneous tissue disorders			
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Pruritus subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 2
Rash subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	2 / 15 (13.33%) 2
Alopecia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Dry skin subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Decubitus ulcer			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	2
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Cold sweat			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Immune-mediated dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Skin lesion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	0 / 6 (0.00%)	2 / 6 (33.33%)	5 / 15 (33.33%)
occurrences (all)	0	6	13
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Urinary retention			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Chronic kidney disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	2
Dysuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Leukocyturia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Micturition disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Renal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Urinary tract pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Urine flow decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			

Hypothyroidism			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 15 (13.33%)
occurrences (all)	0	1	2
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 15 (6.67%)
occurrences (all)	1	1	1
Back pain			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	4 / 15 (26.67%)
occurrences (all)	1	1	4
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Muscular weakness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Muscle spasms			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Bursitis			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Muscle atrophy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1
Rheumatoid arthritis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Infections and infestations			
COVID-19 subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	4 / 15 (26.67%) 6
Pneumonia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Clostridium difficile infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	2 / 15 (13.33%) 2
Sinusitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Eye infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Abscess subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0
Bacteriuria subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0

Bronchitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Herpes simplex			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Kidney infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pneumonia aspiration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0

Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 6 (16.67%)	3 / 6 (50.00%)	9 / 15 (60.00%)
occurrences (all)	1	3	9
Hypokalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	5 / 15 (33.33%)
occurrences (all)	0	0	8
Hyponatraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Hyperuricaemia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	4 / 15 (26.67%)
occurrences (all)	0	1	4
Hypomagnesaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	4 / 15 (26.67%)
occurrences (all)	0	0	4
Dehydration			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 15 (13.33%)
occurrences (all)	0	1	4
Hyperglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	3 / 15 (20.00%)
occurrences (all)	0	0	3
Hypoalbuminaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	2
Hyperkalaemia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Hyperphosphataemia			

subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Hypoglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Hypocalcaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	2
Food intolerance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Dose Expansion Phase: Cohort B1: Thoracic NETs	Dose Expansion Phase: Cohort B2: GEP NETs	Dose Expansion Phase: Cohort C: SCLC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	20 / 20 (100.00%)	15 / 15 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm skin			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	3 / 10 (30.00%)	9 / 20 (45.00%)	1 / 15 (6.67%)
occurrences (all)	7	37	1
Flushing			
subjects affected / exposed	2 / 10 (20.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	2	3	0
Hypotension			

subjects affected / exposed	0 / 10 (0.00%)	3 / 20 (15.00%)	0 / 15 (0.00%)
occurrences (all)	0	3	0
Orthostatic hypotension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Vasculitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	5 / 10 (50.00%)	11 / 20 (55.00%)	7 / 15 (46.67%)
occurrences (all)	11	14	8
Oedema peripheral			
subjects affected / exposed	1 / 10 (10.00%)	7 / 20 (35.00%)	0 / 15 (0.00%)
occurrences (all)	2	12	0
Asthenia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	2 / 15 (13.33%)
occurrences (all)	0	1	2
Pyrexia			
subjects affected / exposed	2 / 10 (20.00%)	3 / 20 (15.00%)	0 / 15 (0.00%)
occurrences (all)	2	3	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	2 / 15 (13.33%)
occurrences (all)	1	2	2
Chills			
subjects affected / exposed	1 / 10 (10.00%)	3 / 20 (15.00%)	0 / 15 (0.00%)
occurrences (all)	1	3	0
Localised oedema			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Malaise			
subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	1	1	0
Gait disturbance			

subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Catheter site haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Catheter site haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Injection site pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Medical device site pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Xerosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			

Seasonal allergy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 20 (10.00%) 2	0 / 15 (0.00%) 0
Hypersensitivity subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Reproductive system and breast disorders			
Pelvic pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 20 (5.00%) 1	0 / 15 (0.00%) 0
Gynaecomastia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3	5 / 20 (25.00%) 7	3 / 15 (20.00%) 3
Dyspnoea subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 4	3 / 20 (15.00%) 3	2 / 15 (13.33%) 2
Epistaxis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 20 (10.00%) 3	0 / 15 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 20 (10.00%) 2	0 / 15 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	1 / 20 (5.00%) 1	0 / 15 (0.00%) 0
Pleural effusion subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Productive cough			

subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	2	2	0
Sinus congestion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Atelectasis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Hiccups			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Pneumonitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Sneezing			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Sputum discoloured			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	2 / 10 (20.00%)	2 / 20 (10.00%)	3 / 15 (20.00%)
occurrences (all)	2	2	5
Insomnia			
subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	2	1	0

Anxiety			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Depressed mood			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Panic attack			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Restlessness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 10 (30.00%)	13 / 20 (65.00%)	1 / 15 (6.67%)
occurrences (all)	11	37	3
Alanine aminotransferase increased			
subjects affected / exposed	2 / 10 (20.00%)	11 / 20 (55.00%)	1 / 15 (6.67%)
occurrences (all)	9	26	2
Blood creatinine increased			
subjects affected / exposed	2 / 10 (20.00%)	7 / 20 (35.00%)	1 / 15 (6.67%)
occurrences (all)	2	24	1
Weight decreased			
subjects affected / exposed	2 / 10 (20.00%)	3 / 20 (15.00%)	1 / 15 (6.67%)
occurrences (all)	7	3	1
Blood bilirubin increased			

subjects affected / exposed	2 / 10 (20.00%)	6 / 20 (30.00%)	1 / 15 (6.67%)
occurrences (all)	5	12	3
Lipase increased			
subjects affected / exposed	2 / 10 (20.00%)	5 / 20 (25.00%)	1 / 15 (6.67%)
occurrences (all)	6	16	2
Platelet count decreased			
subjects affected / exposed	4 / 10 (40.00%)	4 / 20 (20.00%)	1 / 15 (6.67%)
occurrences (all)	4	9	1
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 10 (10.00%)	5 / 20 (25.00%)	0 / 15 (0.00%)
occurrences (all)	1	9	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	3 / 10 (30.00%)	4 / 20 (20.00%)	0 / 15 (0.00%)
occurrences (all)	7	6	0
Amylase increased			
subjects affected / exposed	2 / 10 (20.00%)	3 / 20 (15.00%)	1 / 15 (6.67%)
occurrences (all)	14	4	1
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 10 (10.00%)	5 / 20 (25.00%)	0 / 15 (0.00%)
occurrences (all)	1	7	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 10 (0.00%)	4 / 20 (20.00%)	0 / 15 (0.00%)
occurrences (all)	0	10	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 10 (0.00%)	4 / 20 (20.00%)	0 / 15 (0.00%)
occurrences (all)	0	6	0
Neutrophil count decreased			
subjects affected / exposed	1 / 10 (10.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	1	6	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	2 / 10 (20.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	3	8	0
White blood cell count decreased			

subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	9	0
Blood creatine increased			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	3	0
Ejection fraction decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Troponin T increased			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Breath sounds abnormal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Fall			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	3	0
Infusion related reaction			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Incision site discharge			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Postoperative wound complication			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Wound dehiscence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	3	0
Aortic valve disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 10 (20.00%)	6 / 20 (30.00%)	4 / 15 (26.67%)
occurrences (all)	2	7	4
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)	6 / 20 (30.00%)	2 / 15 (13.33%)
occurrences (all)	0	8	2
Dysgeusia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Tremor			

subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	1	0	1
Hypoaesthesia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Lethargy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	2
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	2
Sciatica			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Burning sensation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Dysarthria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Metabolic encephalopathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Spinal cord compression			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	3 / 10 (30.00%)	4 / 20 (20.00%)	1 / 15 (6.67%)
occurrences (all)	3	11	1
Coagulopathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Hypacusis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Vertigo			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Ear pruritus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Vision blurred			
subjects affected / exposed	1 / 10 (10.00%)	2 / 20 (10.00%)	1 / 15 (6.67%)
occurrences (all)	1	2	1
Vitreous floaters			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	5 / 10 (50.00%)	12 / 20 (60.00%)	6 / 15 (40.00%)
occurrences (all)	10	17	12
Diarrhoea			
subjects affected / exposed	3 / 10 (30.00%)	11 / 20 (55.00%)	6 / 15 (40.00%)
occurrences (all)	15	19	8
Vomiting			
subjects affected / exposed	3 / 10 (30.00%)	6 / 20 (30.00%)	4 / 15 (26.67%)
occurrences (all)	4	10	6
Abdominal pain			

subjects affected / exposed	4 / 10 (40.00%)	4 / 20 (20.00%)	5 / 15 (33.33%)
occurrences (all)	8	6	5
Constipation			
subjects affected / exposed	2 / 10 (20.00%)	2 / 20 (10.00%)	3 / 15 (20.00%)
occurrences (all)	2	2	3
Flatulence			
subjects affected / exposed	1 / 10 (10.00%)	2 / 20 (10.00%)	1 / 15 (6.67%)
occurrences (all)	1	2	1
Abdominal distension			
subjects affected / exposed	0 / 10 (0.00%)	3 / 20 (15.00%)	1 / 15 (6.67%)
occurrences (all)	0	4	1
Dry mouth			
subjects affected / exposed	2 / 10 (20.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	2	1	0
Stomatitis			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	3	0
Abdominal pain upper			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	3	0
Dysphagia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	1	0	1
Haematochezia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorder			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Ileus			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Large intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Mouth haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Odynophagia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pancreatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Proctalgia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Rectal haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Small intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			

Immune-mediated hepatitis subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 3	2 / 20 (10.00%) 3	0 / 15 (0.00%) 0
Biliary obstruction subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Hepatic artery thrombosis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Hepatic cirrhosis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Skin and subcutaneous tissue disorders			
Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	3 / 20 (15.00%) 3	0 / 15 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 20 (0.00%) 0	1 / 15 (6.67%) 1
Rash subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	2 / 15 (13.33%) 2
Alopecia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 20 (10.00%) 2	0 / 15 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 20 (0.00%) 0	1 / 15 (6.67%) 1
Decubitus ulcer subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Palmar-plantar erythrodysaesthesia syndrome subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 20 (10.00%) 2	0 / 15 (0.00%) 0
Cold sweat			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Immune-mediated dermatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	4 / 10 (40.00%)	9 / 20 (45.00%)	0 / 15 (0.00%)
occurrences (all)	5	47	0
Haematuria			
subjects affected / exposed	0 / 10 (0.00%)	5 / 20 (25.00%)	1 / 15 (6.67%)
occurrences (all)	0	5	1
Urinary retention			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Acute kidney injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Chronic kidney disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0

Dysuria			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Hydronephrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Leukocyturia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Micturition disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Renal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Urinary tract pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Urine flow decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	3 / 10 (30.00%)	8 / 20 (40.00%)	1 / 15 (6.67%)
occurrences (all)	4	24	1
Back pain			
subjects affected / exposed	1 / 10 (10.00%)	4 / 20 (20.00%)	0 / 15 (0.00%)
occurrences (all)	1	7	0
Pain in extremity			
subjects affected / exposed	2 / 10 (20.00%)	4 / 20 (20.00%)	0 / 15 (0.00%)
occurrences (all)	2	8	0
Myalgia			
subjects affected / exposed	1 / 10 (10.00%)	3 / 20 (15.00%)	0 / 15 (0.00%)
occurrences (all)	2	4	0
Muscular weakness			
subjects affected / exposed	1 / 10 (10.00%)	3 / 20 (15.00%)	0 / 15 (0.00%)
occurrences (all)	1	4	0
Flank pain			
subjects affected / exposed	2 / 10 (20.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	2	1	0
Neck pain			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Muscle spasms			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Muscle atrophy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Rheumatoid arthritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0

Infections and infestations COVID-19 subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	3 / 20 (15.00%) 3	1 / 15 (6.67%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	1 / 15 (6.67%) 1
Pneumonia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 20 (5.00%) 2	0 / 15 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 20 (10.00%) 3	0 / 15 (0.00%) 0
Clostridium difficile infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 20 (10.00%) 3	0 / 15 (0.00%) 0
Eye infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	1 / 15 (6.67%) 1
Abscess subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Bacteriuria subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Cellulitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 15 (0.00%) 0
Conjunctivitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Cystitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Herpes simplex			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Kidney infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pneumonia aspiration			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Rash pustular			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			

Decreased appetite subjects affected / exposed occurrences (all)	4 / 10 (40.00%) 10	11 / 20 (55.00%) 13	3 / 15 (20.00%) 3
Hypokalaemia subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	5 / 20 (25.00%) 8	2 / 15 (13.33%) 2
Hyponatraemia subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	7 / 20 (35.00%) 36	3 / 15 (20.00%) 7
Hyperuricaemia subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 6	3 / 20 (15.00%) 7	0 / 15 (0.00%) 0
Hypomagnesaemia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	4 / 20 (20.00%) 6	1 / 15 (6.67%) 1
Dehydration subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	1 / 20 (5.00%) 1	4 / 15 (26.67%) 4
Hyperglycaemia subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 8	5 / 20 (25.00%) 17	0 / 15 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	3 / 20 (15.00%) 4	0 / 15 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	3 / 20 (15.00%) 3	0 / 15 (0.00%) 0
Hyperphosphataemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	4 / 20 (20.00%) 11	0 / 15 (0.00%) 0
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	4 / 20 (20.00%) 4	0 / 15 (0.00%) 0
Hypophosphataemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	4 / 20 (20.00%) 6	0 / 15 (0.00%) 0

Hypercalcaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Hypocalcaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Food intolerance			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Dose Expansion Phase: Cohort D: GC	Dose Expansion Phase: Cohort E2: UPS	Dose Expansion Phase: Cohort F: ATC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	8 / 9 (88.89%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 3 (33.33%)	4 / 9 (44.44%)	2 / 3 (66.67%)
occurrences (all)	4	8	4
Flushing			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vasculitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 3 (100.00%)	4 / 9 (44.44%)	1 / 3 (33.33%)
occurrences (all)	4	6	2
Oedema peripheral			
subjects affected / exposed	1 / 3 (33.33%)	3 / 9 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	4	0
Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	4 / 9 (44.44%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	2
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Medical device site pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Xerosis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Pelvic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gynaecomastia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	3 / 9 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	5	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Atelectasis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sneezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Insomnia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Anxiety			
subjects affected / exposed	1 / 3 (33.33%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Depression			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Depressed mood subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0
Irritability subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Panic attack subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Restlessness subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0
Product issues Device occlusion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 2	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	1 / 3 (33.33%) 2
Weight decreased subjects affected / exposed occurrences (all)	2 / 3 (66.67%) 2	1 / 9 (11.11%) 2	0 / 3 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 9 (0.00%) 0	1 / 3 (33.33%) 2
Lipase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	2 / 3 (66.67%) 3
Platelet count decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	3
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			

subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Troponin T increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Haemoglobin decreased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	5	0
Neutrophil count increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Incision site discharge			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Postoperative wound complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Wound dehiscence			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Aortic valve disease			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 3 (0.00%)	3 / 9 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lethargy			

subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Burning sensation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolic encephalopathy			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Sinus headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
Spinal cord compression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	1 / 3 (33.33%)
occurrences (all)	0	2	1
Coagulopathy			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Thrombocytosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0
Ear and labyrinth disorders			
Hypoacusis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Ear pruritus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Vitreous floaters subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	1 / 3 (33.33%) 2
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	3 / 3 (100.00%) 4	4 / 9 (44.44%) 7	0 / 3 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	3 / 3 (100.00%) 7	4 / 9 (44.44%) 16	1 / 3 (33.33%) 1
Vomiting subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	3 / 9 (33.33%) 5	0 / 3 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	2 / 3 (66.67%) 3	2 / 9 (22.22%) 2	0 / 3 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	3 / 9 (33.33%) 3	2 / 3 (66.67%) 2
Flatulence			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	1 / 3 (33.33%)
occurrences (all)	0	3	1
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Ascites			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Gingival bleeding			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ileus			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Large intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mouth haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Odynophagia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Oral pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pancreatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Proctalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Small intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Immune-mediated hepatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Biliary obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Hepatic artery thrombosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Hepatic cirrhosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Skin and subcutaneous tissue disorders			
Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 2	1 / 9 (11.11%) 2	1 / 3 (33.33%) 1
Pruritus subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 2	2 / 9 (22.22%) 2	0 / 3 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Alopecia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Decubitus ulcer subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Palmar-plantar erythrodysaesthesia syndrome subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Cold sweat subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Dermatitis acneiform subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Hyperhidrosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Immune-mediated dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Psoriasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	1 / 3 (33.33%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	1	10	0
Haematuria			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Urinary retention			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chronic kidney disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Leukocyturia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Micturition disorder			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Nephrolithiasis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Urinary tract pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urine flow decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Pain in extremity			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Muscular weakness			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Flank pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Bursitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle atrophy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rheumatoid arthritis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Clostridium difficile infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Sinusitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Bacteriuria			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Bronchitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Conjunctivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Folliculitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Gastrointestinal viral infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Herpes simplex subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Kidney infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0
Pneumonia aspiration subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Rash pustular subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0
Sepsis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0
Skin infection subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	3 / 3 (100.00%) 3	3 / 9 (33.33%) 4	1 / 3 (33.33%) 1
Hypokalaemia subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0
Hyponatraemia			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Hyperuricaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypomagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Dehydration			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypocalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Food intolerance			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 March 2021	The purpose of this amendment was to align the protocol across sponsor programs (inclusion/exclusion criteria) and to make administrative corrections to errors identified in the original protocol, v 1.
10 October 2021	The purpose of this amendment was to add a cohort in the dose expansion phase to further evaluate the efficacy and safety of surufatinib, to define the RP2D, to align the protocol across sponsor programs and to make administrative changes.
16 March 2022	The purpose of this amendment was to update the inclusion criteria, to provide guidance for diagnosis and management of infusion-related and hypersensitivity reactions and immune-related adverse events, to update the company name following a change, and to make administrative changes.
30 November 2022	The purpose of this amendment was to provide notification that further enrollment to all study cohorts was halted based upon the strategic evaluation of surufatinib in the United States and Europe with HUTCHMED as the study Sponsor. This change was not based on any concern for patient safety or efficacy relative to surufatinib treatment. Currently enrolled patients who were deriving clinical benefit from treatment with surufatinib could continue to participate in the study as per the protocol. There was no planned interruption in the supply of surufatinib to clinical trial sites with active patients.
29 November 2023	The purpose of this amendment was to provide notification of the termination of this study based on the strategic re-evaluation of the clinical development of surufatinib in the United States and Europe. This change was not based on any concern for patient safety or efficacy relative to surufatinib and/or tislelizumab treatment.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated based on the strategic re-evaluation of the clinical development of surufatinib in the United States and Europe with no safety concerns.

Notes: